Researchers Jonathan E. Knikman

Jonathan E. Knikman

Assistant Professor

Biography

Jonathan Knikman, PhD, PharmD, Clinical Pharmacologist, works as an assistant professor at the Julius Center for Health Sciences & Primary Care, Department of Public Global Health & Bioethics. Trained as a pharmacist, clinical pharmacologist, a PhD in clinical pharmacology and precision medicine, and currently pursuing a masters in (clinical) epidemiology, his current work focuses on the personalised medicine of antihypertensive drugs.

Jonathan Knikman ensures the scientific coordination of the clinical trial (WP5) in the Hypermarker project, focused on personalised pharmacometabolomic optimisation of treatment for hypertension. Furthermore, he is also involved in the study of the influence of nutrition on the effectiveness of antihypertension drugs (WP3) and the prediction of response to antihypertensive drugs (WP4).

Contact

jknikman@umcutrecht.nl

Pure profile

Recent publications

All publications

Predictors of poor treatment tolerability in older patients receiving fluoropyrimidine-based chemotherapy Joosje C Baltussen, Jonathan E Knikman, Nienke A de Glas, Mirjam de With, Arnold Baars, Geert-Jan Creemers, Helga J Droogendijk, Edward Fiets, Liselot van Iersel-Valkenburg, Caroline M P W Mandigers, Alexander L T Imholz, Marlene H W van de Poel, Frank J F Jeurissen, Machteld Wymenga, Peter Nieboer, Tessa Tigges, Eeke Wesseling, Jan H M Schellens, Jesse J Swen, Henk-Jan Guchelaar, Ron H J Mathijssen, Hans Gelderblom, Simon P Mooijaart, Annemieke Cats, Johanneke E A Portielje
Journal of geriatric oncology, 2026, vol. 17

Dietary modification of blood pressure-lowering effects of antihypertensive drugs - a scoping review Bristi Miah, Johanna M Marianne Geleijnse, Diederick E Grobbee, Yvonne T van der Schouw, Jonathan E Knikman,
Journal of Hypertension, 2026, vol. 44, p.717-730

Response to Letter Re Niels Heersche, Ron H.J. Mathijssen, Annemieke Cats, Henk Jan Guchelaar, Jonathan E. Knikman
European Journal of Cancer, 2025, vol. 230

Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels Jonathan E Knikman, Mirjam de With, Niels Heersche, Marta Lopez-Yurda, Arnold Baars, Geert-Jan Creemers, Helga J Droogendijk, Edward Fiets, Alexander L T Imholz, Liselot Valkenburg-van Iersel, Caroline M P W Mandigers, Alina J van de Vendel, Frank J F Jeurissen, Peter Nieboer, Maarten J Deenen, Marlène H W van de Poel, Machteld N M Wymenga, Ron H N van Schaik, Bianca J C van den Bosch, Esther Oomen-de Hoop, Hilde Rosing, Jesse J Swen, Hans Gelderblom, Jan H M Schellens, Jos H Beijnen, Ron H J Mathijssen, Henk-Jan Guchelaar, Annemieke Cats
European Journal of Cancer, 2025, vol. 224

Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type Edwin Brokaar, Jonathan Knikman, Loes Visser, Frederiek van den Bos, Linda Henricks, Carin Lunenburg, Femke de Man, Hans Gelderblom, Jan Schellens, Ron Mathijssen, Henk-Jan Guchelaar, Johanneke Portielje, Annemieke Cats, Wout Postmus, Nienke de Glas
Fundamental and Clinical Pharmacology, 2025, vol. 39

A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens Jonathan E Knikman, Marta Lopez-Yurda, Didier Meulendijks, Maarten J Deenen, Jan H M Schellens, Jos Beijnen, Annemieke Cats, Henk-Jan Guchelaar
Clinical Pharmacology and Therapeutics, 2024, vol. 115, p.269-277